Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies

This study is examining how well a combination of immune checkpoint drugs (like PD-1/PD-L1 inhibitors), anti-blood vessel drugs, and a liver procedure called TACE work together for advanced liver cancer (HCC) that has spread outside the liver or invaded blood vessels. The goal is to develop a better way to predict which patients will benefit most from this treatment combination. **You may be eligible if...** - You have been diagnosed with hepatocellular carcinoma (HCC) at BCLC stage C (advanced, with spread outside the liver or blood vessel involvement) - You have not previously received any systemic therapy for HCC - You have received at least one cycle of combination immunotherapy/anti-angiogenesis therapy - You have undergone TACE (a procedure that delivers treatment directly to the liver) in combination with the above drugs - You have measurable liver lesions on imaging **You may NOT be eligible if...** - You have previously received systemic cancer treatments - You do not have measurable disease Talk to your doctor to see if this trial is right for you.